Fujifilm Commits to Further Research on Nucleic Acid-liposome drug delivery system
January 2, 2018
FUJIFILM Corporation (President: Kenji Sukeno) announced today that Fujifilm is working towards improving the development of nucleic acid therapeutics by using liposomal drug delivery systems. Fujifilm’s liposomal drug delivery systems are created from its expertise in advanced nanodispersion and analytical technologies. The drug delivery formulation is also used in its anti-cancer drug candidate “FF-10832”, a liposomal gemcitabine formulation, which is being evaluated in a US Phase 1 clinical trial.
In support of these continuing efforts, Fujifilm has engaged in a research collaboration with the Anderson Lab at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). The new research project is focused on nucleic acid therapeutics with the Koch Institute for Integrative Cancer Research (Koch Institute, hereafter). Leading the project at the Anderson Laboratory is Professor Daniel G. Anderson, Ph.D., Associate Professor, Chemical Engineering and Institute for Medical Engineering and Science, a leading researcher in the field of new materials for medicine, and in particular nanoparticulate delivery of drugs and macromolecules. The project will also be advised by Professor Robert S. Langer, Sc.D., a leader and expert on drug delivery systems and regenerative medicine.
Both Anderson and Langer are members of the Koch Institute, a research center that brings together biologists and chemists along with biological, chemical, mechanical, and materials science engineers, computer scientists, clinicians and others, to bring fresh perspectives and an interdisciplinary approach to advancing the fight against cancer.
The goal of the research is to create revolutionary nucleic acid therapies by combining Fujifilm expertise and the scientific knowledge of Anderson Laboratory to develop methods to efficiently deliver nucleic acids to specific areas of the body. In this research, Fujifilm will combine its expertise in formulation sciences with that of the Anderson Laboratory to develop technology that targets delivery of nucleic acids to specific organs and cells. The ultimate goal of this research will be to create nucleic acid therapeutics with broad applications in the clinic.
For inquiries on information in this media release, contact:
U.S. Media Contact: Christine Jackman Tel (914) 261-4959
Media Contact: Corporate Communications Division Tel +81-3-6271-2000
Other Contact: Pharmaceutical Products Division Tel +81-3-6271-2171